The role of antifibrinolytics in trauma haemorrhage and early coagulopathy remains controversial with respect to patient selection, dosage, timing of treatment, and risk of thrombotic complications. This review presents our current understanding of the mechanisms of fibrinolysis in trauma, diagnostic evaluation, and the evidence base for treatment.
INTRODUCTION
Our understanding of the central role played by the fibrinolytic system following traumatic injury has evolved substantially over the past two decades. Severe trauma results in a massive activation of the fibrinolytic system [1], contributing to the development of Acute Traumatic Coagulopathy (ATC) [2 && ] and exacerbation of bleeding. Haemorrhage represents the leading cause of preventable death because of injury and excessive fibrinolysis is a contributing factor in up to 40% of all deaths from trauma [3] . Empiric transfusion therapy and targeted therapy for bleeding have seen antifibrinolytic drugs [4] adopted into trauma practice guidelines worldwide [5 && ], supported by a large evidence base. However, debate continues on the role such therapeutics have in part because of an incomplete understanding of the drivers of the fibrinolytic response following injury, and the absence of a diagnostic tool capable of accurate and timely quantification of fibrinolytic activity. This review will outline our present understanding of fibrinolysis in trauma, evidence-based practice, current controversies in management, and future research directions.
THE FIBRINOLYTIC SYSTEM
Fibrinolysis describes the cleavage of the proenzyme plasminogen into its active form, plasmin, under the control of the primary physiological activators tissue-type plasminogen activator (tPA) and urinarytype plasminogen activator. Plasmin is essential for vascular homeostasis, required for the timely breakdown of fibrin clots following coagulation to maintain vascular patency. Both tPA and plasminogen bind to the surface of fibrin which acts as a cofactor for tPA with the net effect being enhanced plasmin generation in the presence of fibrin [6] . In this manner, the fibrinolytic system is selfregulating with fibrin being both degraded by plasmin as well as initiating and accelerating fibrinolysis. Control of the fibrinolytic system is achieved through the inhibitory action of plasminogen activator inhibitor 1 (PAI-1) on tPA, a-2-antiplasmin (a2AP) on plasmin and thrombin activatable fibrinolysis inhibitor which indirectly limits fibrin breakdown [6] . Following major trauma, shock in combination with tissue injury results in massive tPA release from intracellular endothelial stores [7] . Concurrent activation of the sympathoadrenal system leads to a catecholamine surge with a resultant 'endotheliopathy' from endothelial activation and glycocalyx damage which further exacerbates coagulopathy and stimulates hyperfibrinolysis [8, 9 & ].
ACUTE TRAUMATIC COAGULOPATHY: FIBRINOLYSIS AND FIBRINOGENOLYSIS
The early and endogenous phenomenon of ATC is identifiable at the time of hospital admission in a quarter of severely injured patients [10] , and dependent on the combination of systemic hypoperfusion and tissue injury [11] . ATC is characterized by systemic hypocoagulation, platelet dysfunction, hyperfibrinolysis, and early fibrinogen depletion [2
&&
,12]. Hypofibrinogenaemia is commonly encountered in bleeding trauma patients, with levels below 2.29 g/l strongly associated with increased mortality [13] . Fibrinogen replacement can ex vivo correct coagulopathy [14] with pilot trial data [15] finding a potential outcome benefit for patients treated with early fibrinogen supplementation. Several larger randomized trials are now underway to assess the efficacy of fibrinogen concentrate and cryoprecipitate in the early phase of haemostatic resuscitation [16] [17] [18] . The exact mechanism of early fibrinogen loss is not clear but hypothermia and acidosis are known to disrupt fibrinogen metabolism [19] and more recently direct fibrinogenolysis [20, 21] has been postulated as a potential mechanism.
Activation of the protein C pathway appears central to the cause of ATC [22, 23] with some mechanistic data demonstrating an important role for activated protein C (aPC) in driving both systemic fibrinolysis and possibly fibrinogen depletion [24 && ]. In addition to its inhibitory effect on thrombin formation, excess aPC acts on the fibrinolytic system by consuming PAI-1, removing the inhibitory hold on fibrinolysis and allowing free tPAmediated plasmin formation [22] . Protein C activation is markedly increased following trauma as a consequence of massive thrombin generation and subsequent complex formation with thrombomodulin at the endothelial surface [25] . In an experimental model of trauma haemorrhage using transgenic mice with reduced capacity to activate protein C, fibrinolysis and fibrinogen depletion were significantly attenuated with relative protection from ATC, confirming a mechanistic role for aPC in hyperfibrinolysis [24 && ].
PLATELETS AND FIBRINOLYSIS
Platelets are critical to haemostasis and although overall count is typically preserved after injury, platelet dysfunction contributes to ATC and is associated with increased mortality [12, 26] . Platelets contain large stores of active PAI-1 within a-granules [27] and in-vitro experiments have shown platelet lysate to attenuate tPA-mediated fibrinolysis [28] . It remains to be elucidated whether this effect relates to release of platelet PAI-1 or is attributable to one of the other clot stabilizing components within platelets (e.g. antiplasmin, thrombin activatable fibrinolysis inhibitor, factor XIII) [29] [30] [31] .
Exogenous platelet transfusions are associated with improved outcomes in patients who receive high ratios of platelets to red blood cells (RBCs) early in damage control resuscitation [32] [33] [34] . In our study of 161 bleeding trauma patients with serial rotational thromboelastometry (ROTEM) sampling during active haemorrhage [35 & ] we found platelet transfusions did not appear to influence platelet aggregation but were associated with a significant reduction in EXTEM maximum lysis (ML). Furthermore, platelet transfusions were associated with increased levels of circulating PAI-1 and reduced tPA levels which may represent a primary
KEY POINTS
Massive fibrinolytic activation occurs in over 80% of severely injured trauma patients.
Fibrinolytic protein biomarkers (e.g. PAP) are the gold standard for assessing hyperfibrinolysis but are currently confined to the research setting.
Point-of-care viscoelastic haemostatic assays (ROTEM and TEG) are faster but relatively insensitive for accurate diagnosis of increased fibrinolytic activation.
Best practice mandates empirical administration of TXA within 3 h of injury to all patients with suspected or confirmed traumatic haemorrhage, an immediate need for transfusion or evidence of haemorrhagic shock.
antifibrinolytic mode of action in conferring outcome benefit. Platelets however are not purely antifibrinolytic but contain plasminogen, plasminogen activators, and a reservoir of plasmin on their surface and therefore have profibrinolytic potential [36 & ]. The net effect of different platelet subpopulations, in different states of activation on regulation of fibrinolysis and how they respond to traumatic injury continues to be an area of active research in trauma science.
DETECTION OF FIBRINOLYSIS
Measurement of fibrinolytic activation in a clinically relevant timescale is challenging and a definitive diagnostic test of fibrinolysis does not yet exist. Most research studies have utilized a combination of either fibrin degradation products (e.g. D-dimer), individual biomarkers of the fibrinolytic system (e.g. tPA, plasmin-a2-antiplasmin) or viscoelastic haemostatic assays (VHAs), for example, ROTEM, TEG to measure fibrinolysis. VHA is increasingly used as part of the haemostatic assessment and guided resuscitation of severely injured patients. Using whole blood it can be deployed as a near patient test to obtain a rapid, global, and functional assessment of coagulation and fibrinolysis. Elevated D-dimers indicate fibrin degradation but tissue injury in trauma patients will increase D-dimer levels and after adjustment for injury severity and degree of shock, D-dimer level alone is incapable of predicting VHA-detectable hyperfibrinolysis [37] . Euglobulin clot lysis time has no role in trauma management because of the long assay time, loss of plasma inhibitors (i.e. antiplasmin) during processing, and inability of the assay to assess response to antifibrinolytics [38] . The relative concentrations of tPA and plasmin-a2-antiplasmin (PAP) to the inhibitors of fibrinolysis (e.g. PAI-1, a2AP) provide the most comprehensive assessment of overall fibrinolytic activity but these assays are not practical for use in clinical care. In addition, protein levels describe previous activation of the fibrinolytic system and do not necessarily represent the current extent of fibrinolysis. Highly accurate and rapid biomarker assays of fibrinolysis are urgently required to diagnose hyper and hypofibrinolytic states.
THE UTILITY AND LIMITATIONS OF VISCOELASTIC HAEMOSTATIC ASSAYS TO DETECT FIBRINOLYSIS
VHAs are currently the only tests able to diagnose hyperfibrinolysis early in a clinically useful timeframe for trauma resuscitation [39] . Various threshold definitions for VHA hyperfibrinolysis have been described [40 & ] with currently accepted definitions being ML more than 15% for ROTEM [41] and clot lysis equal or greater than 3% (Ly30 3%) for TEG [42] , above which increased transfusion requirements and higher mortality have been described [1, 42] . However, at present there is a lack of evidence to support the routine use of VHA in trauma [43 & 45, 46 & ]. Using a composite measure of PAP and ROTEM ML, we identified 'severe' fibrinolysis (ROTEM positive, PAP positive) in only 5% of patients. However, 57% of patients had evidence of 'moderate' or occult fibrinolysis (ROTEM negative, PAP positive) with a 12-fold higher mortality compared with those having normal PAP and ML. ROTEM detects hyperfibrinolysis only after massive activation of the fibrinolytic system, when elevated tPA levels (approx. five times normal) combine with depleted antiplasmin levels (<75% of normal) [1] . Rapid inhibition of free tPA by PAI-1 following blood draw [47] results in lesser degrees of fibrinolytic activation being undetectable by VHA. A further consideration is the variability in sensitivity to fibrinolysis between different VHAs, for example, RapidTEG is resistant to tPA-induced fibrinolysis which may lead to under-reporting of hyperfibrinolysis [48] . Modifications to existing assays such as a TEG assay spiked with exogenous tPA [49 & ] have been described but require further validation. Improving the sensitivity of existing VHAs or development and testing of a new point-of-care diagnostic tool capable of rapidly quantifying the degree of fibrinolytic activity is urgently required.
At the opposite end of the fibrinolytic spectrum, patients exhibiting VHA detected hypofibrinolysis on hospital admission [46 & ] have received recent attention and stimulated much discussion within the trauma community as to the potential impact on treatment (e.g. appropriateness of antifibrinolytics) and patient outcomes [50, 51] . Phenotyping those patients with VHA hypofibrinolysis according to injury pattern, physiological characteristics, and their coagulation and fibrinolytic biomarker profiles is required to better understand this cohort of patients. Patients presenting with ROTEM hypofibrinolysis represent a heterogeneous group of patients in terms of injury pattern and severity, fibrinolytic protein levels, and clinical outcomes [52] . Understanding the temporal patterns of the
ANTIFIBRINOLYTIC TREATMENT
Currently the only evidence-based treatment of hyperfibrinolysis in trauma is with the antifibrinolytic tranexamic acid (TXA). A synthetic lysine analogue, TXA competitively blocks the lysine-binding site on plasminogen, preventing its conversion to plasmin. It is a cheap, well tolerated drug which has been prescribed in a variety of clinical settings over the past five decades [53, 54] . In trauma, the largest body of evidence for TXA comes from the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH)-2 trial which randomized 20 211 injured patients with confirmed or suspected haemorrhage to receive intravenous TXA or placebo [4] . The overall mortality rate was lower in patients receiving TXA (14.5 vs. 16%) as was the overall risk of death because of bleeding (4.9 vs. 5.7%) with the greatest benefit seen in hypotensive patients (SBP <75 mmHg). In a recently published multicentre observational study, treatment with TXA and transfusion of high ratios of platelets or plasma to RBCs were independently associated with increased survival and decreased need for massive transfusion [55 && ]. Given the lack of a sufficiently accurate or rapid diagnostic test for fibrinolysis, administration of TXA should be based on best available clinical evidence. Data from trials in civilian patients (including CRASH-2) [4, 56] and military studies [57, 58] . In a study of 222 bleeding trauma patients, we have shown that early empiric TXA reverses VHA hyperfibrinolysis both on Emergency Department (ED) admission and after a massive transfusion (after 12 RBC units) [61] . TXA was associated with lower Ddimer levels, maintained clot strength after massive transfusion, and provided a degree of protection from trauma-induced coagulopathy.
Timing of TXA administration is crucial with the survival benefit greatest when TXA is delivered early, within the first hour from injury, with an as yet unexplained negative effect on outcome when TXA is administered beyond 3 h (CRASH-2 data). The negative outcomes associated with late TXA could be a surrogate marker of poorer outcomes associated with delayed trauma care or TXA could potentiate the evolving prothrombotic state. Following the initial hypocoagulable and hyperfibrinolytic phase of ATC, postresuscitation patients subacutely switch to a hypercoagulable state whereby they are predisposed to thrombotic complications such as venous thromboembolism (VTE) [62] . Polytrauma patients have a baseline risk of VTE that exceeds 50% with no thromboprophylaxis [63] , with increasing age an important clinical predictor [64] . As trauma care advances and more patients survive beyond 24 h from the initial traumatic insult, the number at risk of developing subsequent VTE will rise. The CRASH-2 trial, identified no increase in rates of clinically significant vascular occlusive events and in the military setting, whereas the Military application of tranexamic acid in trauma emergency resuscitation study [57] reported higher unadjusted rates of VTE in casualties receiving TXA this difference was not significant on multivariate analysis. Rather than omitting antifibrinolytics during the initial hyperfibrinolytic phase, future research should address the role of proactive-targeted thromboprophylaxis (e.g. use of retrievable vena cava filters, tailored dosing of prophylactic anticoagulants) as these high-risk patients transition into a hypercoagulable and hypofibrinolytic state. Improved diagnostics to track changes in the coagulation and fibrinolytic status during this transition period would be of additional value.
FIBRINOLYSIS IN TRAUMATIC BRAIN INJURY
Traumatic brain injury (TBI) is a leading cause of trauma deaths and is associated with coagulopathy in up to two-thirds of patients on ED admission [65 && ]. The coexistence of coagulopathy is a poor prognostic indicator for patients with TBI, associated with progressive haemorrhagic injury [66] and mortality rates ranging from 17-86% [65 && ]. Hyperfibrinolysis is a key feature of coagulopathy in TBI although the precise mechanisms are unclear. Overlap is likely with those driving systemic ATC and hyperfibrinolysis in addition to release of tissue factor from injured brain tissue into the systemic circulation [67] , temporal changes in levels of tPA and urinary-type plasminogen activator [68 & ], and depletion of antiplasmin [69, 70] .
Meta-analysis of two randomized trials examining the effect of TXA on outcomes following TBI showed a significant reduction in intracranial haemorrhage progression but no statistically significant improvement of clinical outcomes [71] . The results of the CRASH-3 trial which is because of complete patient enrolment at the end of 2017 are eagerly awaited and should provide important evidence as to the effect of TXA on mortality and disability in patients with TBI as well as the risk of vascular occlusive events and seizures [72] .
BENEFITS OF TRAUMATIC BRAIN INJURY BEYOND HEMOSTASIS
There is a growing appreciation of the interactions between the coagulation, fibrinolytic and immune systems in response to trauma. Plasmin not only degrades fibrin but also can additionally activate inflammatory cells such as monocytes, macrophages and dendritic cells, and stimulate the production of cytokines and free radical species, highlighting the importance of the fibrinolytic system in inflammation, immune response, and elimination of infections [73] .
Trauma patients who survive the initial insult of traumatic haemorrhage frequently develop multiple organ dysfunction syndrome (MODS) and sepsis as a consequence of the overwhelming systemic inflammatory response and suppression of the body's ability to fight infections [74,75 & ] . In a prospective cohort study of severely injured patients, empiric administration of TXA was associated with a reduction in MODS and all-cause mortality in shocked patients [56] . The survival benefit and reduction in myocardial infarction rates observed in the CRASH-2 trial may be partly attributable to an anti-inflammatory effect of TXA. Measurement of gene expression in patients undergoing cardiac surgery has shown that antifibrinolytics are associated with less upregulation of proinflammatory and more upregulation of anti-inflammatory genes [76] . In an animal model of traumatic haemorrhage, TXA has been shown to attenuate the loss of lung barrier function with the result being reduced levels of inflammatory proteins associated with acute lung injury measured in the lungs of rats resuscitated with TXA [77] . Future studies to understand the knock-on effect that early massive fibrinolytic activation has on the immune system are additionally warranted and could lead to the development of new therapeutics capable of attenuating both the acute fibrinolytic and inflammatory responses to trauma.
CONCLUSION
Profound fibrinolytic activation is almost universal following severe trauma and is one of the key characteristics of ATC. Hyperfibrinolysis is driven by the combination of tissue injury and haemorrhagic shock and appears to be mediated by activation of the protein C pathway. Measurement of fibrinolytic activity by biomarkers (e.g. PAP) is the current gold standard although not practical in the clinical management of bleeding trauma patients. Currently available point-of-care platforms (ROTEM or TEG) are insensitive in their detection of fibrinolytic activity and therefore their sole use cannot be recommended to guide treatment of hyperfibrinolysis. Clinical trial evidence supports the use of empirically administered TXA as the mainstay for treatment of trauma-induced fibrinolysis. Administration of TXA is recommended early in all patients with confirmed or suspected traumatic haemorrhage, those requiring immediate blood transfusion and severely injured patients exhibiting haemorrhagic shock. The potential benefits of TXA beyond the bloodstream are an exciting area of ongoing research that is likely to lead to a greater understanding of the interactions between fibrinolysis and inflammation and potentially to the discovery of new therapeutics to improve trauma patient survival.
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